Medical Management of Benign Prostatic Hyperplasia

March 2024 in “ Cleveland Clinic journal of medicine ”

Eiftu Haile, Ayodeji E. Sotimehin, Bradley C. Gill

TLDR Alpha-blockers and 5-alpha reductase inhibitors are main treatments for BPH, with new support for phosphodiesterase-5 inhibitors and beta-3 agonists.

Medical management of benign prostatic hyperplasia (BPH) has advanced, with alpha-blockers and 5-alpha reductase inhibitors remaining primary treatments. New evidence supports the use of phosphodiesterase-5 inhibitors and beta-3 agonists for additional symptom relief. This review focuses on the indications, benefits, and side effects of these pharmacotherapies, while surgical treatments are discussed elsewhere.

View this study on ccjm.org →

Discuss this study in the Community →

Related Research

3 / 3 results

research A Review on Finasteride: A 5-Alpha Reductase Inhibitor, Its Mechanism, Facts, and Benefits

June 2019 in “Journal of Drug Delivery and Therapeutics”

Finasteride effectively treats hair loss and prostate issues with minimal side effects.

research Effect of MK-386, a Novel Inhibitor of Type 1 5 Alpha-Reductase, Alone and in Combination with Finasteride, on Serum Dihydrotestosterone Concentrations in Men

7 citations, August 1996 in “The Journal of Clinical Endocrinology and Metabolism”

research Effect of Finasteride, a 5 Alpha-Reductase Inhibitor, on Serum Gonadotropins in Normal Men

9 citations, August 1992 in “The Journal of Clinical Endocrinology and Metabolism”